The aim of the call is to establish a number of ambitious, innovative, multi-disciplinary and multinational collaborative research projects that aim at understanding the biomedical, psychological and/or social mechanisms of non-pharmaceutical interventions in order to identify potential target sites for enhanced personalized interventions or a combination of pharmacological and nonpharmacological interventions. Proposals must focus on one or several of the following neurodegenerative diseases:

• Alzheimer's disease and other dementias
• Parkinson's disease and PDrelated disorders
• Prion diseases
• Motor neuron diseases
• Huntington's disease
• Spinocerebellar ataxia (SCA)
• Spinal muscular atrophy (SMA)

Proposals submitted under this call may include, but are not limited to, the following types of research:

• Using the potential from existing animal and cellular models and cohorts, including available data and biomaterial, for conducting largescale OMICS approaches to unravel the interplay and interactions of molecules from multiple molecular levels driving disease pathogenesis.
• Better understanding the complex and multifactorial mechanisms of disease onset and progression as well as the corresponding influencing factors.
• Translating the findings from Big Data analysis and multiOMICS approaches to existing animal and cellular models, thereby enhancing the potential of these models.
• Identification of new drug targets or novel starting points for pharmacological interventions and prevention.
• Sharpening the current understanding of disease definition, thus leading to enhanced subclassification and better patient stratification.
• Identification of novel and validation of already established biomarkers.

Eligible countries for this call are: Australia, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Slovakia, Spain, Switzerland and Turkey.

Proposals may be submitted by research groups working in universities or other higher education institutions, non-university public or private research organisations, hospitals and other health and social care settings, as well as commercial companies, in particular small and mediumsize enterprises (SMEs). Collaborations with companies from outside the traditional medical sector (e.g. computing, artificial intelligence) are welcome.

Consortia may consist of partners who receive funding for research by funding organisations participating in this joint call ("regular partners") as well as non-funded external collaborators. Regular partners are represented by the leaders of individual research groups (typically a principal investigator or a young academic group leader) within individual institutions. Each regular partner must verify their eligibility to request funding from one of the funding organisation(s) of their respective country participating in the call (see section one). If different research groups from the same institution request funding, these groups will be treated as separate regular partners under this call.

Each proposal must involve a minimum of three and a maximum of six regular partners, including the coordinator, from at least three different countries participating in this call. However, if the proposal involves at least one regular partner from an EU-13 country (Czech Republic, Hungary, Poland and Slovakia) or from Turkey, the maximum number of regular partners is extended to seven. For reasons of transnational balance, no more than two regular partners from the same country are allowed to join a proposal.

In case of interest, both as possible coordinator or partner, please click on "m'interessa" and we will contact you.